×
About 16,660 results

ALLMedicine™ Gout Center

Research & Reviews  6,693 results

MiR-223-3p inhibits inflammation and pyroptosis in monosodium urate-induced rats and fi...
https://doi.org/10.1111/cei.13587
Clinical and Experimental Immunology; Tian J, Zhou D et. al.

Feb 20th, 2021 - Down-regulated miR-223-3p was found in rheumatoid arthritis. This study aimed to further explore the level and role of miR-223-3p in gout arthritis (GA). After monosodium urate (MSU)-induced GA rat and fibroblast-like synoviocytes (FLSs) model wer...

The Use of Colchicine in Cardiovascular Diseases - a Systematic Review.
https://doi.org/10.1016/j.amjmed.2021.01.019
The American Journal of Medicine; Siak J, Flint N et. al.

Feb 20th, 2021 - The medicinal properties of colchicine have been recognized for centuries. While previously used for gout and familial Mediterranean fever, its immune-modulating, anti-inflammatory, and antifibrotic effects are increasingly recognized to benefit c...

A randomized, phase 2 study evaluating the efficacy and safety of anakinra in the treat...
https://doi.org/10.1002/art.41699
Arthritis & Rheumatology (Hoboken, N.J.); Saag KG, Khanna PP et. al.

Feb 19th, 2021 - To evaluate anakinra efficacy and safety compared to triamcinolone in the treatment of gout flares. Patients unsuitable for NSAIDs and colchicine were enrolled in this multi-center, randomized, double-blind study lasting for up to 2 years (NCT0300...

LncRNAs Landscape in the patients of primary gout by microarray analysis.
https://doi.org/10.1371/journal.pone.0232918
PloS One; Qing YF, Zheng JX et. al.

Feb 18th, 2021 - To determine the expression profile and clinical significance of long non-coding RNAs (lncRNAs) in peripheral blood mononuclear cells (PBMCs) of patients with primary gout and healthy control subjects. Human lncRNA microarrays were used to identif...

The effect of immunomodulators on the efficacy and tolerability of pegloticase: a syste...
https://doi.org/10.1016/j.semarthrit.2021.01.005
Seminars in Arthritis and Rheumatism; Keenan RT, Botson JK et. al.

Feb 18th, 2021 - Pegloticase is a recombinant PEGylated uricase that converts relatively insoluble urate to highly water-soluble allantoin, which is readily excreted by the kidneys. It is the first and only biologic treatment indicated for refractory or uncontroll...

see more →

Guidelines  47 results

Comparative Performances of Sodium-Glucose Cotransporter-2 Inhibitors in Reducing Gout in Type 2 Diabetes
https://www.rheumatologyadvisor.com/home/conference-highlights/acr-convergence-2020/comparative-performance-of-sglt2-inhibitors-in-reducing-gout-in-t2d/

Nov 8th, 2020 - Among patients with type 2 diabetes (T2D), sodium-glucose cotransporter-2 (SGLT2) inhibitors dapagliflozin and empagliflozin vs canagliflozin show greater benefit in reducing gout, according to research results presented at the American College of...

Managing Gout
https://www.jwatch.org/na51787/2020/06/11/managing-gout
NEJM Journal Watch;

Jun 10th, 2020 - The ACR has updated its 2012 guideline on managing gout. Each recommendation is rated as “strong” (supported by moderate- or high-certainty evidence) or “conditional” (benefits and risks are closely balanced, or only low-certainty evidence or no d...

2020 American College of Rheumatology Guideline for the Management of Gout.
https://doi.org/10.1002/art.41247
Arthritis & Rheumatology (Hoboken, N.J.); FitzGerald JD, Dalbeth N et. al.

May 11th, 2020 - To provide guidance for the management of gout, including indications for and optimal use of urate-lowering therapy (ULT), treatment of gout flares, and lifestyle and other medication recommendations. Fifty-seven population, intervention, comparat...

Rising Incidence of Acute Hospital Admissions due to Gout
http://www.jrheum.org/content/47/4/619.long
The Journal of Rheumatology; Russell MD

Mar 31st, 2020 - To describe trends in acute hospital admissions due to gout in England, with rheumatoid arthritis (RA) as a comparator, alongside prescribing trends for common gout medications.

Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
https://www.nejm.org/doi/full/10.1056/NEJMoa1912388?query=featured_home
New England Journal of Medicine; Tardif JC et al

Nov 16th, 2019 - Experimental and clinical evidence support the role of inflammation in atherosclerosis and its complications. Colchicine is an orally administered, potent antiinflammatory medication that is indicated for the treatment of gout and pericarditis.

see more →

Drugs  575 results see all →

Clinicaltrials.gov  8,079 results

Naproxen - naproxen tablet-REMEDYREPACK INC.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88a548d1-97c0-46d0-825a-75ef689d6470

Feb 21st, 2021 - Naproxen tablets and naproxen sodium tablets are indicated for: the relief of the signs and symptoms of: rheumatoid arthritis osteoarthritis ankylosing spondylitis Polyarticular Juvenile Idiopathic Arthritis Naproxen tablets and naproxen sodium ta...

Allopurinol - allopurinol tablet-Preferred Pharmaceuticals Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62866c84-fec3-4c1b-9b8b-65c0372bc8f9

Feb 21st, 2021 - THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA. Allopurinol tablets USP reduces serum and urinary uric acid concentrations. Its use should be individualized for each patient and requires an und...

Allopurinol - allopurinol tablet-Preferred Pharmaceuticals Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eb1b1aa6-cbd3-4b06-b9f9-9a0779a2da08

Feb 21st, 2021 - THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA. Allopurinol tablets USP reduces serum and urinary uric acid concentrations. Its use should be individualized for each patient and requires an und...

MiR-223-3p inhibits inflammation and pyroptosis in monosodium urate-induced rats and fi...
https://doi.org/10.1111/cei.13587
Clinical and Experimental Immunology; Tian J, Zhou D et. al.

Feb 20th, 2021 - Down-regulated miR-223-3p was found in rheumatoid arthritis. This study aimed to further explore the level and role of miR-223-3p in gout arthritis (GA). After monosodium urate (MSU)-induced GA rat and fibroblast-like synoviocytes (FLSs) model wer...

The Use of Colchicine in Cardiovascular Diseases - a Systematic Review.
https://doi.org/10.1016/j.amjmed.2021.01.019
The American Journal of Medicine; Siak J, Flint N et. al.

Feb 20th, 2021 - The medicinal properties of colchicine have been recognized for centuries. While previously used for gout and familial Mediterranean fever, its immune-modulating, anti-inflammatory, and antifibrotic effects are increasingly recognized to benefit c...

see more →

News  1,217 results

Association Between Gout and Comorbidities is Independent of Serum Urate Level
https://www.medscape.com/viewarticle/943485

Jan 3rd, 2021 - Takeaway Cardiovascular comorbidities and chronic kidney disease (CKD) associate with increasing serum urate (SU) in modest (e.g. 1 mg/dl) increments.

Weight Loss May Be Paramount Lifestyle Change in Preventing Gout
https://www.medscape.com/viewarticle/943128

Dec 22nd, 2020 - A recent analysis of the incidence of gout in men, published in JAMA Network Open, offers new insights on the role of lifestyle changes in preventing gout, particularly the importance of obesity and its modification. Prior gout research, although ...

Colchicine a Case Study for What's Wrong With US Drug Pricing
https://www.medscape.com/viewarticle/941885

Dec 1st, 2020 - Public spending on colchicine has grown exponentially over the past decade despite generics suggesting an uphill slog for patients seeking access to long-term therapy for gout or cardiac conditions. Medicaid spending on single-ingredient colchicin...

Gout Clinical Practice Guidelines (ACR, 2020)
https://reference.medscape.com/viewarticle/941449

Nov 23rd, 2020 - Guidelines for managing gout were published in June 2020 by the American College of Rheumatology (ACR).[1] Indications for Pharmacologic Urate-Lowering Therapy (ULT)   Initiating ULT is strongly recommended for gout patients with ≥1 subcutaneous t...

Comparative Performances of Sodium-Glucose Cotransporter-2 Inhibitors in Reducing Gout in Type 2 Diabetes
https://www.rheumatologyadvisor.com/home/conference-highlights/acr-convergence-2020/comparative-performance-of-sglt2-inhibitors-in-reducing-gout-in-t2d/

Nov 8th, 2020 - Among patients with type 2 diabetes (T2D), sodium-glucose cotransporter-2 (SGLT2) inhibitors dapagliflozin and empagliflozin vs canagliflozin show greater benefit in reducing gout, according to research results presented at the American College of...

see more →

Patient Education  49 results see all →